|Day Low/High||107.66 / 113.10|
|52 Wk Low/High||53.06 / 123.99|
Exact Sciences Corp. (NASDAQ: EXAS) today announced that the Centers for Medicare and Medicaid Services (CMS) Advisory Panel on Clinical Diagnostic Laboratory Tests voted unanimously to maintain Medicare's current crosswalk...
Exact Sciences Corp. (NASDAQ: EXAS) today announced that Cologuard was awarded a Wisconsin Innovation Award (WIA) in the "Healthcare/Health IT" category at the second annual ceremony held on August 18, 2015 at...
The most recent short interest data has been released by the NASDAQ for the 07/31/2015 settlement date, which shows a 3,864,520 share decrease in total short interest for EXACT Sciences Corp. , to 23,105,130, a decrease of 14.33% since 07/15/2015.
Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will participate in two investor conferences during August.
Although shares of Exact Sciences have fallen 18% over the past month, its cancer screening product Cologuard is already in use at the Mayo Clinic.
Exact Sciences (EXAS) shares have pulled back in the past month due to a secondary offering and profit taking after a huge run-up.
Cramer says the problem with General Electric is that it's doing nothing.
Cramer is not worried about Apple, and suggests viewers sit back and wait until the post-earnings panic subsides.
Exact Sciences (EXAS) shares are lower following the pricing of the company's 7 million share public offering.
Exact Sciences Corporation (NASDAQ: EXAS) today announced that Jefferies LLC and Robert W.
Exact Sciences Corporation (NASDAQ: EXAS) today announced an agreement to sell 7,000,000 shares of its common stock to Jefferies LLC and Robert W.
Exact Sciences Corp. (Nasdaq: EXAS) today announced its business and financial results for the second quarter of 2015, and showed continued strong performance with more than 21,000 completed Cologuard tests for the quarter,...
Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will host webcasts and conference calls to discuss its second-quarter 2015 financial results and of its annual stockholders meeting.
The trading panel discussed Micron's awful earnings, which Chinese stocks to buy and whether eBay will do better or worse after it spins off PayPal.
Shares of Exact Sciences (EXAS) are gaining after Canaccord raised its 2015 earnings estimates to $1.63 from $1.55, with 2016 earnings estimates increased to $1.09 from $0.99.
The US Preventive Services Task Force, or USPSTF, is expected to publish its revised guidelines for colorectal cancer, or CRC, screening in the third quarter of 2015.
Trade-Ideas LLC identified Exact (EXAS) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate
Exact Sciences Corp. (Nasdaq: EXAS) today announced that it expects to end the second quarter of 2015 with approximately 21,000 completed Cologuard tests.
Trade-Ideas LLC identified Exact (EXAS) as a new lifetime high candidate
Shares of Exact Sciences (EXAS) are climbing after Canaccord raised its price target to $32 from $30, while maintaining its 'buy' rating.
Exact Sciences Corp. (Nasdaq: EXAS) today announced that it will provide a live video webcast and conference call for its Investor & Analyst Day on June 25.
Cramer thinks Gigamon stays hot and hasn't backed away from Biogen Idec.
The May job number is just the start of what could be another tough day, Cramer warns.
Exact Sciences Corp. (NASDAQ: EXAS) and The University of Texas MD Anderson Cancer Center today announced an agreement to jointly develop and commercialize blood-based screening and diagnostic tests for the early...
The Fast Money panel saw opportunities in the white-hot semiconductor industry and also considered the struggling casino industry -- in Macau and abroad.
Exact Sciences Corp. (Nasdaq: EXAS) today announced that it will participate in three investor conferences during June to highlight the company's commercial strategy that's driving the strong early growth of Cologuard.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.